TELA

+ Watchlist + Portfolio

TELA Bio, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.65
52-Week Range: $0.50 – $2.00
Market Cap: $28.70M
P/E (TTM): —
EPS (TTM): -0.77
Dividend Yield: —

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: —
Return on Assets: -33.40%
Gross Margin: 68.29%
Operating Margin: -48.12%
Profit Margin: -51.53%
Current Ratio: 2.99
Debt/Equity: —
Total Debt: $57.92M
Free Cash Flow: $-17.71M
Revenue Growth: -4.50%
Earnings Growth: —
Enterprise Value: $56.19M

TELA Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$41.42M	$58.45M	$69.30M	$80.28M
Cost of Revenue	$14.37M	$18.34M	$22.81M	$25.93M
Gross Profit	$27.04M	$40.11M	$46.49M	$54.34M
Research & Development	$8.94M	$9.62M	$8.81M	$9.22M
Selling, General & Admin	$57.11M	$74.57M	$79.37M	$78.88M
Operating Expenses	$66.05M	$84.19M	$88.18M	$88.10M
Operating Income	-$39.01M	-$44.08M	-$41.70M	-$33.76M
EBITDA	-$39.06M	-$40.63M	-$31.68M	-$32.35M
Pretax Income	-$44.30M	-$46.66M	-$37.98M	-$38.60M
Income Tax	$0.00	$0.00	-$144.00K	$230.00K
Net Income	-$44.30M	-$46.66M	-$37.84M	-$38.83M
Diluted EPS	-2.72	-2.04	-1.33	-0.83
Diluted Shares	16.27M	22.87M	28.53M	46.95M

TELA Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$42.02M	$46.73M	$52.67M	$50.84M
Receivables	$6.62M	$9.74M	$10.10M	$10.35M
Inventory	$11.79M	$13.16M	$12.78M	$11.02M
Current Assets	$62.45M	$71.73M	$78.07M	$75.58M
Total Assets	$67.86M	$78.05M	$86.57M	$81.42M
Current Liabilities	$12.40M	$16.97M	$15.60M	$17.98M
Long-Term Debt	$39.92M	$40.52M	$41.12M	$55.65M
Total Debt	$40.26M	$41.08M	$41.67M	$56.18M
Total Liabilities	$53.55M	$59.17M	$58.11M	$75.11M
Retained Earnings	-$274.23M	-$320.89M	-$358.73M	-$397.56M
Shareholders' Equity	$14.30M	$18.88M	$28.46M	$6.31M
Working Capital	$50.04M	$54.76M	$62.47M	$57.61M
Net Debt	—	—	—	$4.81M

TELA Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$40.75M	-$40.86M	-$41.59M	-$28.22M
Capital Expenditure	-$1.87M	-$611.00K	-$989.00K	-$448.00K
Free Cash Flow	-$42.62M	-$41.47M	-$42.58M	-$28.67M
Depreciation & Amortisation	$1.19M	$808.00K	$1.01M	$1.01M
Stock-Based Compensation	$3.99M	$5.03M	$4.36M	$3.80M
Investing Cash Flow	-$1.87M	-$599.00K	$4.45M	$846.00K
Financing Cash Flow	$40.85M	$46.27M	$43.06M	$25.75M
Net Change in Cash	-$1.77M	$4.81M	$5.91M	-$1.62M

TELA Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$18.52M	$20.20M	$20.69M	$20.87M	$19.06M
Cost of Revenue	$6.01M	$6.09M	$6.72M	$7.11M	$6.54M
Gross Profit	$12.51M	$14.11M	$13.97M	$13.76M	$12.52M
Research & Development	$2.54M	$2.20M	$2.35M	$2.13M	$2.34M
Selling, General & Admin	$20.44M	$20.98M	$19.18M	$18.27M	$20.70M
Operating Expenses	$22.98M	$23.19M	$21.52M	$20.40M	$23.05M
Operating Income	-$10.47M	-$9.08M	-$7.55M	-$6.65M	-$10.53M
EBITDA	-$9.73M	-$8.43M	-$7.15M	-$7.03M	-$9.90M
Pretax Income	-$11.21M	-$9.89M	-$8.60M	-$8.90M	-$12.21M
Income Tax	$52.00K	$33.00K	$0.00	$145.00K	$60.00K
Net Income	-$11.26M	-$9.92M	-$8.60M	-$9.04M	-$12.27M
Diluted EPS	-0.25	-0.22	-0.19	-0.17	-0.21
Diluted Shares	45.27M	45.37M	45.42M	51.68M	57.26M

TELA Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$42.83M	$34.98M	$29.71M	$50.84M	$39.54M
Receivables	$10.56M	$11.24M	$11.27M	$10.35M	$9.71M
Inventory	$13.53M	$11.37M	$11.56M	$11.02M	$12.21M
Current Assets	$69.75M	$60.74M	$56.05M	$75.58M	$64.30M
Total Assets	$77.25M	$67.54M	$61.59M	$81.42M	$69.89M
Current Liabilities	$16.54M	$19.06M	$16.98M	$17.98M	$17.83M
Long-Term Debt	$41.27M	$38.05M	$41.49M	$55.65M	$55.87M
Total Debt	$41.81M	$41.90M	$42.02M	$56.18M	$56.39M
Total Liabilities	$59.13M	$58.35M	$60.03M	$75.11M	$75.09M
Retained Earnings	-$369.99M	-$379.92M	-$388.52M	-$397.56M	-$409.83M
Shareholders' Equity	$18.12M	$9.18M	$1.56M	$6.31M	-$5.20M
Working Capital	$53.21M	$41.68M	$39.07M	$57.61M	$46.47M
Net Debt	—	$6.41M	$11.78M	$4.81M	$16.32M

TELA Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$9.72M	-$7.91M	-$5.72M	-$4.87M	-$11.17M
Capital Expenditure	-$32.00K	-$114.00K	-$211.00K	-$91.00K	-$119.00K
Free Cash Flow	-$9.76M	-$8.02M	-$5.93M	-$4.96M	-$11.29M
Depreciation & Amortisation	$267.00K	$270.00K	$248.00K	$225.00K	$264.00K
Stock-Based Compensation	$1.04M	$985.00K	$955.00K	$812.00K	$816.00K
Investing Cash Flow	$138.00K	$204.00K	$312.00K	$192.00K	$190.00K
Financing Cash Flow	-$116.00K	-$3.00K	$24.00K	$25.84M	-$298.00K
Net Change in Cash	-$9.70M	-$7.70M	-$5.38M	$21.17M	-$11.28M

Market Snapshot

About

TELA Bio, Inc. is a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials for soft tissue reconstruction. The company manufactures OviTex, a portfolio of advanced reinforced tissue matrices that improve clinical outcomes in hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery. TELA uses ovine rumen as a biomaterial scaffold.